对慢性阻塞性肺疾病（COPD）患者进行为期2年的系统性和支气管嗜酸性粒细胞炎症监测：需关注的问题较少。
Monitoring COPD patients systemic and bronchial eosinophilic inflammation in a 2-year follow-up: few concerns.
作者信息
Balan Divya, Manu Mohan K
机构信息
Department of Respiratory Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
出版信息
BMC Pulm Med. 2025 May 16;25(1):235. doi: 10.1186/s12890-025-03717-7.
Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up" by Pignatti et al. provides valuable insights about changes in blood and sputum eosinophils in mild to moderate COPD patients and treatment outcomes. However, concerns arise regarding the accuracy of diagnosis of COPD in subjects with a significant bronchodilator response despite FEV1/FVC ≤ 70%. Although statistically significant differences in FEV1/FVC were observed, the clinical relevance needs scrutiny. Despite a clinically meaningful difference in FEV1 between ICS-treated and untreated patients, the lack of statistical significance raises questions. Addressing these concerns will strengthen the study's reliability and interpretation.
皮尼亚蒂等人所著的《慢性阻塞性肺疾病患者的监测：2年随访中的全身和支气管嗜酸性粒细胞炎症》提供了关于轻度至中度慢性阻塞性肺疾病患者血液和痰液嗜酸性粒细胞变化以及治疗结果的宝贵见解。然而，对于尽管FEV1/FVC≤70%但支气管扩张剂反应显著的受试者中慢性阻塞性肺疾病诊断的准确性存在担忧。尽管观察到FEV1/FVC有统计学显著差异，但临床相关性仍需仔细审查。尽管接受吸入性糖皮质激素（ICS）治疗和未治疗的患者之间FEV1存在临床意义上的差异，但缺乏统计学显著性引发了疑问。解决这些担忧将增强该研究的可靠性和解读。
Zotero 插件